Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010

Blood

Volumn 106, Issue 5, 2005, Pages 1538-1543

  Kaplan, Lawrence D ^a   Lee, Jeannette Y ^b   Ambinder, Richard F ^b   Sparano, Joseph A ^b   Cesarman, Ethel ^b   Chadburn, Amy ^b   Levine, Alexandra M ^b   Scadden, David T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD4 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAPSONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PENTAMIDINE; PREDNISONE; PROTEIN BCL 2; PROTEINASE INHIBITOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANDIDIASIS; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFECTION RISK; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOBACTERIOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 23944508056     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1437     Document Type: Article

References (26)

1. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy, part I. Oncology. 2002;16:441-459.
2. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United States. MMWR Morb Mortal Wkly Rep. 1985;34:373-375.
3. Appleby P, Beral V, Newton R, Reeves G. Highly active antiretroviral therapy and the incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
4. Ledergerber B, Telenti A, Egger M. Risk of HIV-related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J. 1999;319:23-24.
5. Gates AE, Kaplan LD. Biology and management of AIDS-associated non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2003;17:821-841.
6. Kaplan LD, Straus DJ, Testa MA. Low-dose vs standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med. 1997;336:1641-1648.
7. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol. 1998;16:3601-3606.
8. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. AIDS Malignancy Consortium. J Clin Oncol. 2001;19:2171-2178.
9. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-163.
10. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Ann Rev Medicine. 2004;55:477-503.
11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Clin Oncol. 1998;16:2825-2833.
12. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
13. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999;26(suppl 14):79-87.
14. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1253.
15. Hyjek E, Chadburn A, Liu YF, Cesarman E, Knowles DM. BCL-6 protein is expressed in precursor T-cell lymphoblsatic lymphoma and in prenatal and postnatal thymus. Blood. 2001;97:270-276.
16. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
17. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996;87:265-267.
18. Zucca E, Bertoni F, Bosshard G, et al. Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. Ann Oncol. 1996;7:1023-1027.
19. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DL-BCL). Blood. 2003;101:4279-4284.
20. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EP-OCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653-4659.
21. Moore DA, Bonepal T, Partsmouth S, Gill J, Gazzard BG. Etiology and natural history of neutropenia in HIV disease: a prospective study. Clin Infect Dis. 2001;32:469-476.
22. Borg C, Ray-Coquard I, Philip I, et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 2004;101:2675-2680.
23. Bower McCall-Peat N, Ryan N, Davies L, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood. 2004;104:2943-2946.
24. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood. 2005;105:1891-1897.
25. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
26. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Johns Hopkins University, Baltimore, MD. Biol Blood Marrow Transplant. 2000;6:628-632.